期刊文献+

AFP阴性肝癌的肿瘤标志物诊断的研究进展 被引量:5

Progress in research of tumor markers for diagnosis of hepatocellular carcinoma in AFP-negative patients
下载PDF
导出
摘要 甲胎蛋白(alpha-fetoprotein,AFP)是肝细胞癌(hepatocellular carcinoma,HCC)的主要标志物,测定血清AFP水平是目前诊断HCC的主要手段.约1/3的HCC患者血清AFP水平正常,即所谓的AFP阴性肝癌,这部分患者的诊断是目前肝癌诊断中需解决的关键问题.多年来,人们一直在寻找能弥补AFP不足的肝癌标志物,以提高HCC的诊断水平.本文综述了有关AFP阴性肝癌的肿瘤标志物诊断研究进展,主要内容包括传统肝癌标志物对AFP阴性肝癌的诊断价值,新肝癌标志物对AFP阴性肝癌的诊断价值,以及对AFP阴性HCC具有潜在诊断价值的生物标志物. Alpha-fetoprotein (AFP) is an important marker for hepatocellular carcinoma (HCC), and the detection of serum AFP is currently the principal method for the diagnosis of HCC. About one-third of HCC patients have normal serum AFP concentration, and the diagnosis of HCC in these patients is challenging. In recent years, many studies have been done to seek other tu- mor markers for HCC. In this paper, we review the recent progress in research of tumor markers for the diagnosis of HCC in AFP-negative patients.
作者 王婷 张焜和
出处 《世界华人消化杂志》 CAS 北大核心 2011年第33期3420-3425,共6页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.81060197 江西省自然科学基金资助项目 No.2010GZY0318
关键词 甲胎蛋白 肝细胞癌 肿瘤标志物 诊断 Alpha-fetoprotein Hepatocellular carcinoma Tumor markers Diagnosis
  • 相关文献

参考文献9

二级参考文献125

共引文献229

同被引文献51

  • 1张琼,叶达伟,常莹,宋宇虎,谢娜,王晓燕,林菊生.PEG10基因在不同转移潜能肝癌细胞中表达的定量分析[J].华中科技大学学报(医学版),2006,35(6):758-760. 被引量:11
  • 2贾筱琴,刘丹,龚卫娟,王正兵,田芳,季明春.主要组织相容复合物Ⅰ类相关基因A与直肠癌发病及病程转归的影响[J].中华消化杂志,2007,27(1):60-61. 被引量:4
  • 3Semela D, Dufour JF. Angiogenesis and hepatocel- lular carcinoma. J Hepato12004. 41:864-880. 被引量:1
  • 4Utsunomiya T, Shimada M, Imura S, Morine Y, Ike- moto T, Mori M. Molecular signatures of noncan- cerous liver tissue can predict the risk for late recur- rence of hepatocellular carcinoma. J Gastroenterol 2010.45:146-152. 被引量:1
  • 5Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PloS one 2011. 6:e21816. 被引量:1
  • 6Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miya- gi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, Hayashi N. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 2008. 99: 1643-1649. 被引量:1
  • 7Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I, Katano M. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular car- cinoma via the NKG2D-MICA/B system. A nticancer Res 2011. 31:2505-2510. 被引量:1
  • 8He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenviron- ments at tumor sites and myeloid-derived suppres- sor cells. J Immuno12010. 184:2281-2288. 被引量:1
  • 9Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L. Increased intratumoral IL-17- producing cells correlate with poor survival in he- patocellular carcinoma patients. J Hepatol 2009. 50: 980-989. 被引量:1
  • 10Kuang DM, Peng C, Zhao Q, Wu Y, Zhu LY, Wang J, Yin XY, Li L, Zheng L. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immu- no12010. 185:1544-1549. 被引量:1

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部